Friday, July 06, 2007

Genome transplant in bacteria

ScienceDaily: Scientists transplant DNA in bacteria
Creation of artificial life brought a step closer by DNA ...
Scientists Swap Genes in Bacteria - washingtonpost.com

June 29, 2007
Scientists Transplant Genome of Bacteria
By NICHOLAS WADE
Correction Appended

Scientists at the institute directed by J. Craig Venter, a pioneer in sequencing the human genome, are reporting that they have successfully transplanted the genome of one species of bacteria into another, an achievement they see as a major step toward creating synthetic forms of life.

Other scientists who did not participate in the research praised the achievement, published yesterday on the Web site of the journal Science. But some expressed skepticism that it was as significant as Dr. Venter said.

His goal is to make cells that might take carbon dioxide out of the atmosphere and produce methane, used as a feedstock for other fuels. Such an achievement might reduce dependency on fossil fuels and strike a blow at global warming.

“We look forward to having the first fuels from synthetic biology certainly within the decade and possibly in half that time,” he said.

Richard Ebright, a molecular biologist at Rutgers University, said the transplantation technique, which leads to the transferred genome’s taking over the host cell, was “a landmark accomplishment.”

“It represents the complete reprogramming of an organism using only a chemical entity,” Dr. Ebright said.

Leroy Hood, a pioneer of the closely related field of systems biology, said Dr. Venter’s report was “a really marvelous kind of technical feat” but just one of a long series of steps required before synthetic chromosomes could be put to use in living cells.

“It’s a really worthy accomplishment, but I hope it doesn’t get hyped to be more than it is,” Dr. Hood said.

One reason for Dr. Venter’s optimism is that he says his institute is close to synthesizing from simple chemicals an entire genome, 580,000 DNA units in length, of a small bacterium, Mycoplasma genitalium. If that genome can be made to take over a bacterium using the method announced today, Dr. Venter should be able to claim that he has made the first synthetic life form. The bacterium would be identical to nature’s version, but would demonstrate how precise control could be achieved over every aspect of the machinery of living cells.

Biologists have long been able to move useful genes into bacteria and other organisms in a process called genetic engineering. The idea of synthetic biology is to carry out genetic engineering in a more extensive and systematic way.

Synthetic biologists, who held their third annual meeting in Zurich, Switzerland, this week, hope to create biochemical processes and then choose the gene sequences that will direct these processes and build the DNA from scratch. The scientists’ goal is to select and reorder the genetic machinery developed by evolution just as an engineer might assemble an efficient circuit board from existing components.

Dr. Venter hopes to lay the basis for a new approach to synthetic biology by first synthesizing whole genomes in the laboratory and then making them take control of, or “boot up,” a living cell. His new report accomplishes the second of the two steps, at least in Mycoplasma. His team, which includes a distinguished biologist, Hamilton Smith, purified the full DNA from one kind of Mycoplasma and showed that it could take control of another, making the host cell switch over to producing proteins specified by the inserted DNA. Dr. Smith said he was not sure whether the inserted genome destroyed the host genome or just made the cell divide, assigning the two genomes to different daughter cells.

Booting up cells with new genomes is a major limitation in synthetic biology, Dr. Venter said. With that hurdle now crossed, it will be possible to “design cells in future to manufacture new types of fuel and break our dependency on oil and do something about carbon dioxide going into the atmosphere.”

Dr. Hood, co-founder of the Institute for Systems Biology in Seattle, said the next step on Dr. Venter’s agenda, putting a functional synthetic genome into an organism, would be more significant.

“Synthesizing a whole chromosome and getting it to function will be a really remarkable step that will be much closer to the golden vision of creating new organisms,” he said.

George Church, a leading systems biologist at the Massachusetts Institute of Technology, said that the new report was “good science” but that it had been achieved in an organism, Mycoplasma, that is unsuitable for industrial uses. As for Dr. Venter’s assertion that his result is “an enabling technique,” Dr. Church said, “The door to synthetic biology is already wide open, and people are pouring through it.”

Dr. Church agreed with Dr. Venter’s forecast that synthetic biologists could produce fuels within 10 years. He noted that LS9 Inc. in San Carlos, Calif., was producing laboratory amounts of petroleumlike fuels in bacteria.

Dr. Venter is more colorful and less publicity shy than most academic biologists. But he has many solid achievements to his credit. They have so far been in sequencing, or decoding, genomes.

He pioneered methods for sequencing the first bacterium, Haemophilus influenzae, and raced the government to a draw in sequencing a draft version of the human genome in June 2000. Though unable to produce a complete version because he was forced out of Celera, the company he headed, Dr. Venter devised a better method than his government-supported rivals, one that has become the standard way to sequence genomes.

Dr. Venter has always sought academic credit by publishing his results in scientific journals and now directs a nonprofit research laboratory in Rockville, Md., the J. Craig Venter Institute. But he has another foot firmly planted in the commercial world. He has set up, and the Venter Institute largely owns, Synthetic Genomics, whose goal is to make alternative fuels to oil and coal. He has also applied for far-reaching patents on the uses of synthetic life forms.

The report today may be less significant if his research team is unable to repeat the success in more useful organisms than the Mycoplasma bacterium. Dr. Church said a quite similar experiment with Escherichia coli, a standard laboratory organism, was accomplished in 1958 by two French scientists, François Jacob and E. L. Wollman.

Dr. Venter’s next goal, creating the first synthetic bacterium, could have broader interest. At the Zurich meeting this week, his colleague Dr. Smith reported progress in synthesizing a Mycoplasma genome from scratch saying, according to a Nature blog, that he had already constructed it in the form of 101 long DNA fragments. When stuck together, they would comprise the whole genome.

Dr. Venter said Dr. Smith had traveled at least that far.

“We are weeks to months away from booting up that chromosome,” Dr. Venter said.

The longest piece of DNA synthesized so far, he explained, is 35,000 units long, whereas the Mycoplasma genome or chromosome is 580,000 units.

The synthetic Mycoplasma, if the Venter team is successful, would be identical to the natural kind and should present no conceivable hazard. But synthetic biology is a technique with potentially far-reaching consequences like environmental effects and misappropriation by terrorists. In addition, the ability to synthesize living organisms may provoke philosophical comment.

Scientists have taken the initiative in assessing the effects with the hope of staying far enough ahead of events to avoid regulation. A report on the possible dangers of synthetic biology is being prepared for the Sloan Foundation by scientists at M.I.T., the Venter Institute and the Center for Strategic and International Studies.

Dr. Venter said that he was filing for many more patents and that his team was trying to scale up methods of synthesizing DNA and “watermarking chromosomes in fun ways to make it unequivocal they are manmade.” He said he had no plans to use Mycoplasma as a production organism and was developing other bacteria.

“This is an area where things will happen at an exponential pace,” he said. “Once people know you can do chromosomal transplants, that will trigger new approaches.”

Others may already have raced ahead using old-fashion genetic engineering to put new genes into standard microbes. Steve delCardayre, vice president for research at LS9, said it had developed a strain of standard industrial microorganism that produced hydrocarbons from treated agricultural waste.

The present strain, which Dr. delCardayre called adolescent, is “very close to meeting an economic threshold” and will be tested in a pilot plant early next year. The youthful microbe already produces an ethanol-like product, at 65 percent of the cost of corn-derived ethanol, Dr. delCardayre said. LS9 fuels, he added, will meet the same diverse needs as petroleum does, can be transported in existing pipelines and be used in existing vehicles.

Correction: June 30, 2007


A picture caption yesterday with a front-page article about a scientific advance in the effort to create synthetic life forms misidentified the scientist pictured. He is J. Craig Venter, who directs the institute that made the breakthrough, not Hamilton Smith, a biologist who worked on the project. The article also misstated the educational affiliation of George Church, a biologist who commented on the research. He is at Harvard Medical School, not M.I.T.

New Method For Reading DNA Sheds Light On How Cells Define Themselves

New Method For Reading DNA Sheds Light On How Cells Define Themselves

Science Daily — As a fertilized egg develops into a full grown adult, mammalian cells make many crucial decisions -- closing doors of opportunity as they adopt careers as liver cells, skin cells, or neurons. One of the most fundamental mysteries in biomedicine is how cells make such different career decisions despite having exactly the same DNA. By using a new kind of genomic technology, a new study unveils a special code -- not within DNA, but within the so-called "chromatin" proteins surrounding it -- that could unlock these mysterious choices underlying cell identity.

A research team led by scientists at the Broad Institute of Harvard and MIT and the Massachusetts General Hospital has created genome-wide chromatin maps for embryonic stem (ES) cells and two cell types derived from them, by applying a powerful new technology for sequencing DNA. The work, published in the July 1st advance online edition of Nature, provides a framework for mapping the complete chromatin landscape of almost any kind of cell. One of the most surprising findings suggests that cells contain an explicit chromatin-based code that reveals the developmental choices they have already made as well as those decisions that lie ahead.

"Unraveling the mysteries of chromatin holds great promise for understanding how cells in the body -- with nearly identical DNA -- assume such different forms and functions," said co-senior author Bradley Bernstein, an associate member at the Broad Institute and an assistant professor at Massachusetts General Hospital and Harvard Medical School. "By applying a new technology for sequencing DNA, we have been able to look across the genome at chromatin, with greater resolution and efficiency than ever before."

Chromatin proteins are more than just packing material for the genome. By virtue of different chemical groups fastened to them, these proteins influence which parts of the double helix are open -- or not -- to the cellular machinery, thus controlling which genes get turned on or off.

To decipher this "epigenetic" code requires ways of determining precisely which chromatin proteins sit at which locations along a cell's DNA. In principle, scientists could infer the locations by using specialized DNA chips. In practice, though, the technique has proven slow and expensive to construct genome-wide maps of mammalian chromatin. But now, a new method of massively parallel DNA sequencing has given rise to a powerful approach for readily churning out whole-genome maps of chromatin structure. The technology -- based on single-molecule sequencing -- makes it possible to read billions of DNA letters simultaneously. "Single molecule-based methods for decoding DNA are now throwing open the doors to a plethora of unexplored questions in chromatin, epigenetics and many other areas of biology," said Bernstein.

Empowered by this new technology, the researchers set out to study chromatin in cells with drastically different behaviors. They analyzed an assortment of chromatin proteins, each with a distinct chemical tag that switches genes either on or off. The scientists examined these proteins in mouse ES cells -- known for their unusual ability to form nearly any tissue -- as well as two other types of descendant cells that are more limited in the developmental paths they can choose.

One of the most remarkable findings involves a way of using chromatin to look into a cell's past to determine the developmental decisions it has already made, and to peer into the future to read its potential choices. The fortuneteller lies in a unique form of modified chromatin known as a "bivalent domain", which marks the control regions of important genes. Such domains merge both activating and repressive chemical tags, keeping genes quiet yet poised for later activity.

Bivalent domains had been noted for their role in ES cells, helping keep these cells' developmental options wide open. But with the new genome-wide chromatin data, the scientists discovered that these domains also function in more specialized kinds of stem cells. In neural stem cells, for example, bivalent domains sit near genes important to various types of brain cells, but are notably absent from genes that would be active only in, say, skin cells or blood cells.

"Looking at a cell through a microscope often cannot tell you what kind of cell it is, or more importantly, what it has the potential to become," said first author Tarjei Mikkelsen, a Broad Institute researcher and a Harvard-MIT Health Sciences and Technology graduate student. "But by decoding its chromatin on a genomic scale, we can now begin to systematically address such questions."

"Our understanding of the basis of cell identity -- the way that a liver cell knows that it is different from a skin cell -- has been rather vague, much like our understanding of heredity was prior to our knowledge of DNA," said Broad Institute director Eric Lander, a co-senior author of the study. "The chromatin maps suggest that it may be possible to directly read out a complete description of all of a cell's past commitments and its future potential. If true, this would have enormous implications for our understanding of developmental biology and for guiding regenerative medicine."

In addition to shedding light on key developmental decisions, chromatin maps also contain other sorts of new biological information. One type of chromatin modification marks not the control regions of genes, but their "bodies" -- from where genes first begin to where they end. The scientists found that these "body" marks identify not only typical genes -- that is, the ones that encode proteins -- but also so-called "non-coding" genes that only produce RNAs. These marks could provide a practical handle for precisely mapping all of the genes in the genome, a task that has proven quite challenging by other methods.

Reference: Mikkelsen et al. (2007) Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature; DOI:10.1038/nature06008

Note: This story has been adapted from a news release issued by Broad Institute of MIT and Harvard.